论文部分内容阅读
一种称为rt-PA(或Ac,ilyse)的新型溶血栓药物最近在澳大利亚上市。用其治疗心脏病发作已引人注目。rt-PA为重组纤维蛋白溶酶原激活剂的简称,它是能利用机体本身的抗凝血因子治疗心脏病发作的第一个溶血栓药物。据欧州,美国及澳大利亚的临床资料表明,应用rt-PA治疗心脏发作能改善心室功能、减少充血性心衰的发生,降低心脏病发作后的死亡率。人体能合成少量的组织纤维蛋白溶酶激活因子(tPA),以溶解正常形成的血栓,但机体不能产生足量的tPA以快速溶解危及生命的血栓。静脉灌注rt-PA后,它能结合到血纤维蛋白上,然后激活纤维蛋白酶原,使其转化成血纤维蛋白酶,随之溶解血纤维蛋白,使血栓溶解。纤维蛋白酶能增强rt-PA的溶血栓作用。rt-PA是仅有的重组DNA技术研制的溶血栓药品,它与t-PA的
A new thrombolytic drug called rt-PA (or Ac, ilyse) was recently launched in Australia. With its treatment of heart attacks have attracted attention. rt-PA is short for recombinant plasminogen activator. It is the first thrombolytic drug that can take advantage of the body’s own anti-clotting factor in the treatment of heart attack. According to European, American and Australian clinical data show that the application of rt-PA treatment of heart attack can improve ventricular function, reduce the incidence of congestive heart failure, reduce post-heart attack mortality. The body can synthesize a small amount of tissue plasminogen activator (tPA) to dissolve normally formed thrombi, but the body can not produce enough tPA to rapidly dissolve life-threatening thrombi. After intravenous infusion of rt-PA, it binds to fibrin, activates fibrinogen, converts it to fibrin, dissolves fibrin, and dissolves the thrombus. Fibrinases enhance the thrombolytic effect of rt-PA. rt-PA is the only thrombolytic drug developed by recombinant DNA technology, which works with t-PA